SCHEMBL24939893

SCHEMBL24939893

Cc1ccc(Cc2sc3ccccc3c2CN2CCN3C(=O)CNC(=O)C3C2)cc1

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ CYP2D6 P10635 1/20 0.34
▸ CHRM1 P11229 1/20 0.34
▸ HTR2A P28223 1/20 0.34
▸ HRH1 P35367 1/20 0.34
▸ NPY1R P25929 4/20 0.34
▸ GAA P10253 2/20 0.34
▸ PARP1 P09874 1/20 0.32
▸ POLB P06746 2/20 0.31
▸ DRD4 P21917 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ OPRM1 P35372 1/20 0.31
▸ PDE5A O76074 1/20 0.30
▸ PDE11A Q9HCR9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24939890 0.93 GSK3A (0.34) CYP2D6CHRM1HTR2AHRH1NPY1R
SCHEMBL24939992 0.91 NPY1R (0.33) CYP2D6CHRM1HTR2AHRH1NPY1R
SCHEMBL24939944 0.91 PTPN1 (0.35) CYP2D6CHRM1HTR2AHRH1NPY1R
SCHEMBL24938953 0.91 NPY1R (0.41) CYP2D6CHRM1HTR2AHRH1NPY1R
SCHEMBL24939986 0.91 CYP2D6 (0.42) CYP2D6CHRM1HTR2AHRH1NPY1R
SCHEMBL23302562 0.87 NPY1R (0.35) NPY1RPARP1
SCHEMBL29695401 0.87 NPY1R (0.35) NPY1RPARP1
SCHEMBL23303909 0.87 NPY1R (0.35) NPY1RPARP1
SCHEMBL24939917 0.85 SMN1; SMN2 (0.36) SMN1; SMN2TDP1CYP2D6CHRM1HTR2A
SCHEMBL24938970 0.85 CYP1A2 (0.38) SMN1; SMN2TDP1CYP2D6NPY1RPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230019094-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME HOLOSMEDIC (KR) 2023-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019094-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCC1 SMN1; SMN2 3242/4885TDP1 3957/4885CYP2D6 4448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback